Pascal Bamford - 29 Aug 2024 Form 3 Insider Report for Akoya Biosciences, Inc. (AKYA)

Role
Chief Clinical Officer
Signature
/s/ Pascal Bamford by Brian McKelligon, Attorney-in-Fact
Issuer symbol
AKYA
Transactions as of
29 Aug 2024
Net transactions value
$0
Form type
3
Filing time
03 Sep 2024, 21:40:25 UTC
Next filing
21 Nov 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding AKYA Common Stock 82,758 29 Aug 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding AKYA Employee Stock Option (Right to Buy) 29 Aug 2024 Common Stock 150,000 $13.34 Direct F1
holding AKYA Employee Stock Option (Right to Buy) 29 Aug 2024 Common Stock 25,000 $12.30 Direct F2
holding AKYA Employee Stock Option (Right to Buy) 29 Aug 2024 Common Stock 15,000 $5.96 Direct F3
holding AKYA Employee Stock Option (Right to Buy) 29 Aug 2024 Common Stock 50,000 $5.35 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option, representing a right to purchase a total of 150,000 shares, became exercisable as follows: one-fourth of the shares vested on September 20, 2022, and the remaining shares vested in 36 equal monthly installments beginning on October 20, 2022.
F2 The option, representing a right to purchase a total of 25,000 shares, became exercisable as follows: one-fourth of the shares vested on February 23, 2024 with the remaining shares vesting in 36 equal monthly installments beginning on March 23, 2024, subject to reporting person's continuous employment.
F3 The option, representing a right to purchase a total of 15,000 shares, became exercisable as follows: one-fourth of the shares vested on May 18, 2024 with the remaining shares vesting in 36 equal monthly installments beginning on June 18, 2024, subject to reporting person's continuous employment.
F4 The option, representing a right to purchase a total of 50,000 shares, becomes exercisable as follows: one-fourth of the shares vests on February 22, 2025 with the remaining shares vesting in 36 equal monthly installments beginning on March 22, 2025, subject to reporting person's continuous employment.